On Friday June 26, Diabetologia, the journal of the European Association for the Study of Diabetes (EASD) published online data from four studies relating to a possible link between a long-acting insulin analog, insulin glargine, and cancer(1). As a basis for such a possible link, an accompanying editorial explains that certain insulin analogs have a structure making them more likely to bind to the IGF-1 receptor which is known to be involved in promoting tumor growth(2).
The details can be read here.
No comments:
Post a Comment